Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally.
Proven track record average dividend payer.
Share Price & News
How has Perrigo's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRGO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PRGO exceeded the US Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: PRGO exceeded the US Market which returned 4.1% over the past year.
Price Volatility Vs. Market
How volatile is Perrigo's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StWhy You Should Leave Perrigo Company plc's (NYSE:PRGO) Upcoming Dividend On The Shelf
3 weeks ago | Simply Wall StResults: Perrigo Company plc Exceeded Expectations And The Consensus Has Updated Its Estimates
1 month ago | Simply Wall StWith EPS Growth And More, Perrigo (NYSE:PRGO) Is Interesting
Is Perrigo undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRGO ($54.28) is trading below our estimate of fair value ($106.24)
Significantly Below Fair Value: PRGO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRGO is poor value based on its PE Ratio (39.2x) compared to the Pharmaceuticals industry average (16.8x).
PE vs Market: PRGO is poor value based on its PE Ratio (39.2x) compared to the US market (15.1x).
Price to Earnings Growth Ratio
PEG Ratio: PRGO is poor value based on its PEG Ratio (3.4x)
Price to Book Ratio
PB vs Industry: PRGO is good value based on its PB Ratio (1.3x) compared to the US Pharmaceuticals industry average (3.2x).
How is Perrigo forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRGO's forecast earnings growth (11.5% per year) is above the savings rate (2.2%).
Earnings vs Market: PRGO's earnings (11.5% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: PRGO's earnings are forecast to grow, but not significantly.
Revenue vs Market: PRGO's revenue (2% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: PRGO's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PRGO's Return on Equity is forecast to be low in 3 years time (10.1%).
How has Perrigo performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRGO has a large one-off loss of $140.9M impacting its March 28 2020 financial results.
Growing Profit Margin: PRGO's current net profit margins (3.8%) are higher than last year (2.4%).
Past Earnings Growth Analysis
Earnings Trend: PRGO has become profitable over the past 5 years, growing earnings by 27.4% per year.
Accelerating Growth: PRGO's earnings growth over the past year (65%) exceeds its 5-year average (27.4% per year).
Earnings vs Industry: PRGO earnings growth over the past year (65%) exceeded the Pharmaceuticals industry 14.5%.
Return on Equity
High ROE: PRGO's Return on Equity (3.3%) is considered low.
How is Perrigo's financial position?
Financial Position Analysis
Short Term Liabilities: PRGO's short term assets ($3.0B) exceed its short term liabilities ($1.6B).
Long Term Liabilities: PRGO's short term assets ($3.0B) do not cover its long term liabilities ($4.0B).
Debt to Equity History and Analysis
Debt Level: PRGO's debt to equity ratio (59.5%) is considered high.
Reducing Debt: PRGO's debt to equity ratio has increased from 49.4% to 59.5% over the past 5 years.
Debt Coverage: PRGO's debt is not well covered by operating cash flow (13.5%).
Interest Coverage: PRGO's interest payments on its debt are well covered by EBIT (3.6x coverage).
What is Perrigo's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PRGO's dividend (1.66%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.75%).
High Dividend: PRGO's dividend (1.66%) is low compared to the top 25% of dividend payers in the US market (4.73%).
Stability and Growth of Payments
Stable Dividend: PRGO's dividends per share have been stable in the past 10 years.
Growing Dividend: PRGO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (61.7%), PRGO's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PRGO's dividends in 3 years are forecast to be well covered by earnings (21.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Murray Kessler (59yo)
Mr. Murray S. Kessler has been the Chief Executive Officer, President and Director of Perrigo Company plc since October 8, 2018. Mr. Kessler had a 30 years of leadership experience in growing consumer prod ...
CEO Compensation Analysis
Compensation vs Market: Murray's total compensation ($USD10.81M) is above average for companies of similar size in the US market ($USD7.43M).
Compensation vs Earnings: Murray's compensation has increased by more than 20% in the past year.
|CEO, President & Director||1.58yrs||US$10.81m||0.012% $851.6k|
|CFO, Principal Accounting Officer & Executive VP||1.17yrs||US$3.48m||0.0019% $141.3k|
|Executive VP & Chief Scientific Officer||1.33yrs||US$2.71m||0.0022% $160.6k|
|Executive Officer||10.58yrs||US$2.51m||0.017% $1.3m|
|Executive VP & President of Consumer Healthcare International||3.25yrs||US$2.48m||0.0082% $607.5k|
|Chief Transformation Officer and Executive Vice President of Global Operations & Supply Chain||4.58yrs||no data||0.0096% $711.8k|
|Senior Director of Technical Operations||8.67yrs||no data||no data|
|Chief Information Officer & Executive VP||13.58yrs||no data||0.011% $847.2k|
|Vice President of Global Investor Relations & Corporate Communications||no data||no data||no data|
|Executive VP||16.75yrs||US$2.77m||0.029% $2.2m|
Experienced Management: PRGO's management team is considered experienced (4.6 years average tenure).
|CEO, President & Director||1.58yrs||US$10.81m||0.012% $851.6k|
|Independent Director||3.25yrs||US$399.98k||0.0058% $432.1k|
|Independent Chairman of the Board||2yrs||US$530.44k||0.0064% $474.3k|
|Independent Director||5.5yrs||US$399.98k||0.0085% $631.9k|
|Independent Director||3.25yrs||US$387.48k||0.0058% $432.1k|
|Independent Director||3.33yrs||US$388.96k||0.020% $1.5m|
|Independent Director||3.5yrs||US$387.48k||0.010% $765.1k|
|Independent Director||1.08yrs||US$359.55k||0.0021% $157.6k|
|Independent Director||3yrs||US$384.48k||0.0054% $403.3k|
Experienced Board: PRGO's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PRGO insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Perrigo Company plc's company bio, employee growth, exchange listings and data sources
- Name: Perrigo Company plc
- Ticker: PRGO
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.399b
- Shares outstanding: 136.31m
- Website: https://www.perrigo.com
Number of Employees
- Perrigo Company plc
- The Sharp Building
- Hogan Place
- Co. Dublin
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PRGO||TASE (The Tel-Aviv Stock Exchange)||Yes||Ordinary Shares||IL||ILS||Dec 1991|
|PRGO||NYSE (New York Stock Exchange)||Yes||Ordinary Shares||US||USD||Dec 1991|
|PIG||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 1991|
|0Y5E||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||USD||Dec 1991|
|PRGO N||BMV (Bolsa Mexicana de Valores)||Common Stock||MX||MXN||Dec 1991|
Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. It provides upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Steripod, and Rembrandt brand names. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/26 14:43|
|End of Day Share Price||2020/05/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.